Screening for prostate cancer may not reduce mortality

doi:10.1136/bmj.332.7533.72-g

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ research articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Fred Charatan

Florida

Screening tests using prostate specific antigen (PSA), with or without digital rectal examination, can increase the detection of cancer, even at early stages of the disease. However, they do not necessarily prolong survival. This is the conclusion of a study published this week in the Archives of Internal Medicine (2006;166:38-43).

John Concato and his team of 12 investigators identified 501 patients out of 71 661 patients at 10 Veterans Affairs medical centres in New England who were given a diagnosis of …